Diagnosis and treatment of 12 cases of fumarate hydratase-deficient renal cell carcinoma
10.3969/j.issn.1009-8291.2023.09.002
- VernacularTitle:延胡索酸水合酶缺陷型肾癌12例诊治分析
- Author:
Yiming GUO
1
;
Tianxiang BI
1
;
Chaoliang WANG
1
;
Qi LI
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
- Publication Type:Journal Article
- Keywords:
fumarate hydratase;
renal cell carcinoma;
fumarate hydratase-deficient renal cell carcinoma;
hereditary leiomyoma renal cell carcinoma syndrome
- From:
Journal of Modern Urology
2023;28(9):742-747
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To summarize and analyze the clinical data of fumarate hydrase-deficient renal cell carcinoma (FH-RCC), so as to improve the understanding of the disease. 【Methods】 General clinical data of 12 FH-RCC patients treated during Mar.2019 and Dec.2021 were retrospectively analyzed, including the imaging, pathological, genetic testing, surgical and adjuvant therapy, and follow-up results. 【Results】 All cases were confirmed with pathology or genetic tests, including 1 case complicated with uterine fibroids, 3 cases with renal cysts, 4 with family history of uterine fibroids and 2 with family history of renal carcinoma. Cysticular irregular density shadows with an enhancement of 25.8 Hu were detected in 4 cases. Of the 7 cases undergoing genetic testing, 2 had embryo and system mutation, 1 had germ line mutation, 1 had system mutation, and 3 had no germ line or system mutation. Radical nephrotomy was performed in 9 cases. The average operation time was 3.8 h, and the average amount of blood loss was 625 mL. Immunotherapy with targeted therapy was conducted in 10 cases, surgery with postoperative adjuvant therapy in 7 cases, and tyrosine kinase inhibitor with immune checkpoint inhibitor (TKI/ICI) in 1 case. All 12 cases were followed up, 3 died of tumor, 1 had no recurrence, 8 showed progress on imaging. 【Conclusion】 FH-RCC is a rare and highly malignancy prone to metastasis. Imaging shows cystic solid space occupying lesions. FH immunohistochemical staining is negative. Genetic testing is needed to confirm the diagnosis. TKI/ICI combination therapy has a good survival benefit.
